Another study, The Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD) in T1D youth, is currently ongoing with the primary objective of evaluating the effects of ultra-low dose IL-2 administration on residual beta-cell function in new-onset patients. The gene discussed is IL2; the disease is diabetes mellitus.